Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bischoff

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Cancer Research|February 11, 1998
Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinomaE D Bischoff, M M Gottardis, T E Moon, et al.
Cancer Research|December 15, 1996
Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligandM M Gottardis, E D Bischoff, M A Shirley, et al.
Ernst Schering Research Foundation Workshop|January 14, 2005
Precursor-directed biosynthesis for the generation of novel glycopetidesE Stegmann, D Bischoff, C Kittel, et al.
Journal of Lipid Research|April 15, 2010
Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout miceEric D Bischoff, Chris L Daige, Mary Petrowski, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 25, 2000
Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyomaS D Gamage, E D Bischoff, K D Burroughs, et al.
The Journal of Biological Chemistry|May 20, 2003
Farnesoid X receptor regulates bile acid-amino acid conjugationParinaz C Pircher, Jennifer L Kitto, Mary L Petrowski, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 13, 2004
Macrophage liver X receptor is required for antiatherogenic activity of LXR agonistsNancy Levin, Eric D Bischoff, Chris L Daige, et al.
Cancer Research|January 1, 1997
A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude miceD R Shalinsky, E D Bischoff, W W Lamph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1996
Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude miceD R Shalinsky, E D Bischoff, M L Gregory, et al.
Amino Acids|February 9, 2007
Nano-structured support materials, their characterisation and serum protein profiling through MALDI/TOF-MSM Najam-Ul-Haq, M Rainer, N Heigl, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer Research|February 11, 1998
Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinomaE D Bischoff, M M Gottardis, T E Moon, et al.
Cancer Research|December 15, 1996
Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligandM M Gottardis, E D Bischoff, M A Shirley, et al.
Ernst Schering Research Foundation Workshop|January 14, 2005
Precursor-directed biosynthesis for the generation of novel glycopetidesE Stegmann, D Bischoff, C Kittel, et al.
Journal of Lipid Research|April 15, 2010
Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout miceEric D Bischoff, Chris L Daige, Mary Petrowski, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 25, 2000
Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyomaS D Gamage, E D Bischoff, K D Burroughs, et al.
The Journal of Biological Chemistry|May 20, 2003
Farnesoid X receptor regulates bile acid-amino acid conjugationParinaz C Pircher, Jennifer L Kitto, Mary L Petrowski, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 13, 2004
Macrophage liver X receptor is required for antiatherogenic activity of LXR agonistsNancy Levin, Eric D Bischoff, Chris L Daige, et al.
Cancer Research|January 1, 1997
A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude miceD R Shalinsky, E D Bischoff, W W Lamph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1996
Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude miceD R Shalinsky, E D Bischoff, M L Gregory, et al.
Amino Acids|February 9, 2007
Nano-structured support materials, their characterisation and serum protein profiling through MALDI/TOF-MSM Najam-Ul-Haq, M Rainer, N Heigl, et al.
Pageof 3